Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2715-2728

  Ochsenbauer, Christina ^a   Edmonds, Tara G ^b   Ding, Haitao ^a   Keele, Brandon F ^c   Decker, Julie ^a   Salazar, Maria G ^a   Salazar Gonzalez, Jesus F ^a   Shattock, Robin ^d   Haynes, Barton F ^e   Shaw, George M ^f   Hahn, Beatrice H ^f   Kappes, John C ^a,b,g,h  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c SAIC FREDERICK INC   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g University of Alabama at Birmingham   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLADISTICS; CONTROLLED STUDY; DNA SYNTHESIS; ENVELOPE GENE; FEMALE; FOUNDER EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MALE; MOLECULAR CLONING; MONOCYTE DERIVED MACROPHAGE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MALE; MOLECULAR SEQUENCE DATA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857830668     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06157-11     Document Type: Article

References (71)

1. Abrahams MR, et al. 2009. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J. Virol. 83:3556-3567.
2. Alkhatib G, et al. 1996. CC CKR5: a RANTES, MIP-1, MIP-1 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
3. Ayinde D, Maudet C, Transy C, Margottin-Goguet F. 2010. Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology 7:35.
4. Bar KJ, et al. 2010. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J. Virol. 84:6241-6247.
5. Bergamaschi A, Pancino G. 2010. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7:31.
6. Bjorndal A, et al. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487.
7. Bol SM, et al. 2009. Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. Virology 390:205-211.
8. Chang J, et al. 1996. Twin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitro. J. Virol. 70:7792-7803.
9. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L. 1997. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J. Virol. 71:1657-1661.
10. Cheng-Mayer C, Quiroga M, Tung JW, Dina D, Levy JA. 1990. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64:4390-4398.
11. Choe H, et al. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
12. Chohan B, et al. 2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79:6528-6531.
13. + T-cell lines determined by the capacity to exploit low concentrations of CCR5. J. Virol. 73:7842-7847.
14. Deng H, et al. 1996. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381:661-666.
15. Derdeyn CA, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022.
16. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
17. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR. 2009. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 83:2575-2583.
18. Duncan CJ, Sattentau QJ. 2011. Viral determinants of HIV-1 macrophage tropism. Viruses 3:2255-2279.
19. Dunfee RL, Thomas ER, Gabuzda D. 2009. Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. Retrovirology 6:69.
20. Dunfee RL, et al. 2006. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. U. S. A. 103:15160-15165.
21. Dunfee RL, et al. 2007. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 367:222-234.
22. Edmonds TG, et al. 2010. Replication-competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13.
23. Eisert V, et al. 2001. Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors. Virology 286:31-44.
24. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
25. Fenyo EM, Albert J, Asjo B. 1989. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 3(Suppl. 1):S5-S12.
26. Ferrari G, et al. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog. 7:e1001273.
27. Fiebig EW, et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
28. Fischer W, et al. 2010. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 5:e12303.
29. Fouchier RA, Brouwer M, Kootstra NA, Huisman HG, Schuitemaker H. 1994. HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. J. Clin. Invest. 94:1806-1814.
30. Frost SD, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102:18514-18519.
31. Ganusov VV, et al. Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J. Virol. 85:10518-10528.
32. Gartner S, et al. 1986. The role of mononuclear phagocytes in HTLV-III/ LAV infection. Science 233:215-219.
33. Gendelman HE, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
34. Goonetilleke N, et al. 2009. The first T cell response to transmitted/ founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-1272.
35. Gorry PR, et al. 2002. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76:6277-6292.
36. Haaland RE, et al. 2009. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 5:e1000274.
37. Haase AT. 2011. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62:127-139.
38. Hladik F, et al. 2007. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26:257-270.
39. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
40. Keele BF, et al. 2009. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206:1117-1134.
41. Koyanagi Y, et al. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822.
42. Laguette N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-657.
43. Lee HY, et al. 2009. Modeling sequence evolution in acute HIV-1 infection. J. Theor. Biol. 261:341-360.
44. Li H, et al. 2010. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog. 6:e1000890.
45. Li Y, et al. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J. Virol. 65:3973-3985.
46. Liu J, et al. 2010. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84:10406-10412.
47. Liu P, et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J. Virol. 85:11196-11207.
48. Martin-Garcia J, Cao W, Varela-Rohena A, Plassmeyer ML, Gonzalez-Scarano F. 2006. HIV-1 tropism for the central nervous system: brainderived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology 346:169-179.
49. + T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
50. Peters PJ, et al. 2004. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusogenicity for macrophages. J. Virol. 78:6915-6926.
51. Peters PJ, et al. 2008. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 5:5.
52. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR. 2007. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J. Neuroimmune Pharmacol. 2:32-41.
53. Peters PJ, et al. 2006. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J. Virol. 80:6324-6332.
54. Sagar M, Wu X, Lee S, Overbaugh J. 2006. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598.
55. Salazar-Gonzalez JF, et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J. Virol. 82:3952-3970.
56. Salazar-Gonzalez JF, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
57. Salazar-Gonzalez JF, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J. Virol. 85: 2751-2763.
58. Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M. 1998. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J. Virol. 72:4633-4642.
59. Simmons G, et al. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dualtropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360.
60. Telesnitsky A, Goff SP. 1997. Reverse transcription and the generation of retroviral DNA, p 121-160. In Coffin JM, et al. (ed), Retroviruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
61. Thomas ER, et al. 2007. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 360:105-119.
62. Valentin A, Albert J, Fenyo EM, Asjo B. 1990. HIV-1 infection of normal human macrophage cultures: implication for silent infection. Virology 177:790-794.
63. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
64. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
65. Wilen CB, et al. 2011. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 85:8514-8527.
66. Williams LM, Cloyd MW. 1991. Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates. Virology 184:723-728.
67. Wood N, et al. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 5:e1000414.
68. Wu X, et al. 1999. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J. Virol. 73:2126-2135.
69. Zack JA, et al. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.
70. + T cells. Science 286:1353-1357.
71. + T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. U. S. A. 101:5640-5645.